NCT05088239|Completed
Deep Inferior Epigastric Artery Flap for Breast Reconstruction
Division of Plastic and Reconstruction Surgery
Loading search results
Division of Plastic and Reconstruction Surgery
Sponsor study identifier
observational
108
0 countries
N/A
Study Start
July 1, 2011
Actual (reported)Primary Completion
December 31, 2019
Actual (reported)Study Completion
December 31, 2020
Actual (reported)Background: There is no consensus on the duration of prophylactic antibiotics for autologous breast reconstruction after mastectomy. We try to standardize prophylactic antibiotics use during breast reconstruction with deep inferior epigastric perforator flap following mastectomy. Methods: This retrospective case series involved 108 patients who underwent immediate breast reconstruction with deep inferior epigastric perforator flap in Ditmanson Medical Foundation Chia-Yi Christian Hospital between 2012 and 2019. Patients were divided into three groups based on prophylactic antibiotic duration: 1 day, 3 days and \>7 days for patients with drains Data were analyzed between January and April, 2021.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1, 2011
Actual (reported)December 31, 2019
Actual (reported)December 31, 2020
Actual (reported)October 6, 2021
Actual (reported)October 21, 2021
Actual (reported)surgical site infection (SSI)
Infection rate of surgical wounds of breast and abdomen.
Patients were then followed up in the outpatient department for 1 year.
In prophylactic antibiotics for drain group (PAD) (n = 15), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative for 10-14 days when the drains were removed from the breast and abdomen.
In the 3-day prophylactic antibiotics group (PA3) (n = 11), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in peri-operative period, and 6-hourly thereafter for 3 days.
In the 1-day prophylactic antibiotics group (PA1) (n = 82), patients received prophylactic cefazolin 1000 mg 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative period and antibiotics were discontinued within 24 hours of surgery.
Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This retrospective study involved 108 patients who underwent immediate DIEP flap breast reconstruction after unilateral or bilateral mastectomy at the Ditmanson Medical Foundation Chia-Yi Christian Hospital between 2012 and 2019.
Chien-Liang Fang, Director
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City, Taiwan
108 participants (actual enrollment reported by the registry).
First Submitted
October 6, 2021
First Posted
October 21, 2021
Study Start
July 1, 2011
Actual (reported)The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2019
Actual (reported)Study Completion
December 31, 2020
Actual (reported)Last Updated
October 21, 2021
Record last verified: 2021-10
Prophylactic antibiotics discontinued within 24 hours after deep inferior epigastric perforator flap reconstruction can prevent surgical site infection occurrence.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: